Natera (NTRA) announced that its genome-based Signatera MRD assay is now covered by Medicare under LCD L38779. This coverage decision applies to Medicare beneficiaries with colorectal cancer, breast cancer, bladder cancer, ovarian cancer, lung cancer, and pan-cancer immunotherapy monitoring, mirroring the pre-existing coverage for Signatera.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NTRA:
- Needham medtech & diagnostics analyst holds analyst/industry conference call
- Investor Stanley Druckenmiller Sells Alphabet (GOOGL) Stake, Loads Up on Taiwan Semi
- Natera price target raised to $210 from $205 at Piper Sandler
- Natera’s Strong Q1 2025 Performance and Strategic Growth Justify Buy Rating
- Natera’s Strong Market Position and Growth Potential Drive Buy Rating and Increased Price Target